Boston Life Sciences Takes Steps to Further Its Focus On Neurology

Company Terminates R&D agreement with FluoroPharma, Inc.

Boston Life Sciences, Inc. (NASDAQ: BLSI), a development stagebiotechnology company, today announced that it has reached anagreement with FluoroPharma, Inc. to terminate a development agreementrelated to FluoroPharma's Positron Emission Tomography (PET) imagingagents. FluoroPharma is an emerging diagnostic discovery company withproprietary PET technology focused primarily on the diagnosis ofcardiovascular disease. In 2004, FluoroPharma agreed to grant BLSI aright of participation in the event that FluoroPharma pursued adevelopment and/or sublicensing agreement for its imaging agents withan established biotechnology or pharmaceutical company. BLSI isprimarily focused on developing products for the diagnosis andtreatment of central nervous system diseases. Cardiovascular imagingis not one of the Company's current strategic areas of focus, andtherefore, BLSI has agreed to terminate its right of participation inexchange for 25,000 shares of FluoroPharma Series A Preferred stock.The Company's arrangements with FluoroPharma bear no relationship toBLSI's own imaging products in development, ALTROPANE(R) andFLUORATEC(TM), for which BLSI has, and will continue to have,exclusive rights.

Mark Pykett, BLSI's President and COO, commented, "Thistransaction continues our efforts to focus on the further growth ofour CNS therapeutic product pipeline and in particular the completionof our Phase III trial for ALTROPANE, a nuclear imaging agent for thediagnosis of Parkinson's disease."

As previously announced, effective June 11, 2005, Marc Lanser,BLSI's Chief Medical Officer, left the company to becomeFluoroPharma's President and CEO.

Boston Life Sciences, Inc. (BLSI) is a biotechnology companyprimarily focused in the research and clinical development ofbiopharmaceutical products for the diagnosis and treatment of centralnervous system, or CNS, diseases.

Statements in this press release regarding management's futureexpectations, beliefs, goals, plans or prospects may constituteforward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. The Company's actual resultscould differ materially from those stated or implied inforward-looking statements due to a number of factors, including thosefactors contained in the Company's Quarterly Report on form 10-Q forthe quarter ended March 31, 2005, filed with the Securities andExchange Commission under the section "Risk Factors," as well as otherdocuments that may be filed by Boston Life Sciences from time to timewith the Securities and Exchange Commission. As a result of suchrisks, the Company's actual results may differ materially from theresults discussed in or implied by the forward-looking statementscontained herein. Forward-looking statements include statementsregarding Boston Life Sciences' expectations, beliefs, intentions orstrategies regarding the future and can be identified byforward-looking words such as "anticipate," "believe," "could,""estimate," "expect," "intend," "may," "should," "will" and "would" orsimilar words. The Company undertakes no obligation to update orrevise any forward-looking statements, whether as a result of newinformation, future events or otherwise.

Our logo, trademarks, and service marks are the property of BostonLife Sciences, Inc. All other trade names, trademarks, or servicemarks are property of their respective owners and are not the propertyof Boston Life Sciences, Inc.